Oclassen Pharmaceuticals Inc. data

Lilly licensed the nucleoside analog from Oclassen in 1992. Under the agreement, Lilly is to provide all funding for worldwide development of oral FIAU for hepatitis B and holds marketing rights outside the U.S., while Oclassen retained the U.S. marketing rights. Lilly also would co-promote in the U.S. any FIAU products for hepatitis B to medical specialists not targeted by Oclassen's sales force. Lilly is to pay development milestones and royalties on sales. ...